ArticleFrontiers in oncology2022
Dynamic FDG-PET imaging for differentiating metastatic from non-metastatic lymph nodes of lung cancer.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Evaluation of a clinically efficient [EJNMMI research · 2026Article
- Dynamic fluorine-18 fluorodeoxyglucose PET for evaluating different-sized metastatic lymph nodes in patients with non-small cell lung cancers.Quantitative imaging in medicine and surgery · 2026Article
- The value of metabolic parameters on dynamicFrontiers in oncology · 2026Article
- Differences in the quantitative parameter of lung lesions in dynamic chest FDG PET/CT imaging: framing protocol, reconstruction algorithm, software processing.Frontiers in oncology · 2026Article
- Leveraging machine learning with dynamic 18F-FDG PET/CT: integrating metabolic and flow features for lung cancer differential diagnosis.European journal of nuclear medicine and molecular imaging · 2025Article
- Case Report: NUTM1-rearranged lung sarcoma: a rare case imaged with dynamic and staticFrontiers in oncology · 2025Article
- Predictive value of radiomics modeling based on dynamic and staticFrontiers in oncology · 2025Article
- Dynamic FDG PET/CT imaging: quantitative assessment, advantages and application in the diagnosis of malignant solid tumors.Frontiers in oncology · 2025Review
- The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.BMC pulmonary medicine · 2024Article
- Increased lesion detectability in patients with locally advanced breast cancer-A pilot study using dynamic whole-body [EJNMMI research · 2024Article
- Clinical feasibility study of early 30-minute dynamic FDG-PET scanning protocol for patients with lung lesions.EJNMMI physics · 2024Article
- The role of dynamic, static, and delayed total-body PET imaging in the detection and differential diagnosis of oncological lesions.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Case report: DynamicFrontiers in oncology · 2024Article
- Diagnostic Value of DynamicDiagnostics (Basel, Switzerland) · 2023Article
- Dynamic and StaticDiagnostics (Basel, Switzerland) · 2023Article
- Glycolytic Plasticity of Metastatic Lung Cancer Captured by NoninvasiveMetabolites · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Methods: One hundred and eight patients with pulmonary nodules were enrolled to perform Results: Among the 135 FDG-avid LNs confirmed by pathology, 49 LNs were non-metastatic, and 86 LNs were metastatic. LN-SUVmax, MBP-SUVmax, LN-SUVmax/MBP-SUVmax, and LN-SUVmax/short diameter couldn't well differentiate metastatic from non-metastatic LNs ( Conclusion: Compared with SUVmax, quantitative parameters such as K
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.